Search
Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigational[L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEnzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance ...
Meclocycline
go.drugbank.com/drugs/DB13092InvestigationalMeclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .
Mebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnIt was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.
Lanolin alcohols
go.drugbank.com/drugs/DB14181ApprovedIt is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.
Penicillamine
go.drugbank.com/drugs/DB00859ApprovedInvestigationalThe pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Synonyms: D-penicillamine, 3-mercapto-D-valineProducts: D-PenamineTafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Moxisylyte
go.drugbank.com/drugs/DB09205ApprovedMoxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. According to the WHO, moxisylyte is approved since 1987 and in the same year, it acquired the denomination of orphan product by t...
Clobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.